{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T21:10:06Z","timestamp":1774732206277,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Sanofi, Paris, France"}],"content-domain":{"domain":["diabetesresearchclinicalpractice.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.diabres.2016.10.022","type":"journal-article","created":{"date-parts":[[2016,11,9]],"date-time":"2016-11-09T12:30:47Z","timestamp":1478694647000},"page":"57-65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100U\/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy"],"prefix":"10.1016","volume":"124","author":[{"given":"David R.","family":"Owens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Traylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Mullins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Landgraf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2016.10.022_b0005","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc14-2441","article-title":"Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"38","author":"Inzucchi","year":"2015","journal-title":"Diabetes Care"},{"issue":"Suppl. 1","key":"10.1016\/j.diabres.2016.10.022_b0010","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.4158\/EP15672.GLSUPPL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology \u2013 Clinical Practice Guidelines for Developing a Diabetes Mellitus Comprehensive Care Plan \u2013 2015","volume":"21","author":"Handelsman","year":"2015","journal-title":"Endocr Pract"},{"issue":"Suppl. 1","key":"10.1016\/j.diabres.2016.10.022_b0015","first-page":"S1","article-title":"Standards of medical care in diabetes \u2013 2016","volume":"39","author":"American Diabetes Association","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2016.10.022_b0020","unstructured":"Agency for Healthcare Research and Quality. Premixed insulin analogues. A comparison with other treatments for type 2 diabetes <http:\/\/effectivehealthcare.ahrq.gov\/repFiles\/Insulin_Clinician5.pdf>; 2009 [accessed 07.06.16]."},{"key":"10.1016\/j.diabres.2016.10.022_b0025","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.diabres.2014.08.003","article-title":"Efficacy and safety of basal insulin glargine 12 and 24 weeks after initiation in persons with type 2 diabetes: a pooled analysis of data from treatment arms of 15 treat-to-target randomised controlled trials","volume":"106","author":"Owens","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabres.2016.10.022_b0030","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/j.1464-5491.2012.03605.x","article-title":"Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy Study","volume":"29","author":"Peyrot","year":"2012","journal-title":"Diabet Med"},{"key":"10.1016\/j.diabres.2016.10.022_b0035","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/j.1463-1326.2010.01232.x","article-title":"Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine","volume":"12","author":"Home","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2016.10.022_b0040","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.2337\/diacare.23.8.1130","article-title":"Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901\/3002 Study Group","volume":"23","author":"Yki-J\u00e4rvinen","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2016.10.022_b0045","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2337\/diacare.24.4.631","article-title":"Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin","volume":"24","author":"Rosenstock","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2016.10.022_b0050","doi-asserted-by":"crossref","first-page":"952","DOI":"10.7326\/0003-4819-138-12-200306170-00006","article-title":"Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes","volume":"138","author":"Fritsche","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.diabres.2016.10.022_b0055","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.2337\/diacare.26.11.3080","article-title":"The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients","volume":"26","author":"Riddle","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2016.10.022_b0060","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.arcmed.2005.10.015","article-title":"Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride","volume":"37","author":"Eliaschewitz","year":"2006","journal-title":"Arch Med Res"},{"key":"10.1016\/j.diabres.2016.10.022_b0065","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.diabres.2006.08.012","article-title":"Insulin glargine versus NPH insulin therapy in Asian type 2 diabetes patients","volume":"76","author":"Pan","year":"2007","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabres.2016.10.022_b0070","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/dom.12329","article-title":"Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-na\u00efve people with type 2 diabetes","volume":"17","author":"Home","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2016.10.022_b0075","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/j.clinthera.2007.08.020","article-title":"Negative binomial meta-regression analysis of a combined glycosylated hemoglobin and hypoglycemia outcome across eleven phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus","volume":"29","author":"Mullins","year":"2007","journal-title":"Clin Ther"},{"issue":"2","key":"10.1016\/j.diabres.2016.10.022_b0080","first-page":"CD005613","article-title":"Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus","author":"Horvath","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.diabres.2016.10.022_b0085","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1464-5491.2007.02341.x","article-title":"Hypoglycaemia in type 2 diabetes","volume":"25","author":"Amiel","year":"2008","journal-title":"Diabet Med"},{"issue":"Suppl. 3","key":"10.1016\/j.diabres.2016.10.022_b0090","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1185\/03007995.2011.621416","article-title":"Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetes","volume":"27","author":"Ross","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.diabres.2016.10.022_b0095","doi-asserted-by":"crossref","first-page":"23","DOI":"10.17925\/EE.2014.10.01.23","article-title":"A patient-level analysis of efficacy and hypoglycaemia outcomes across treat-to-target trials with insulin glargine added to oral antidiabetes agents in people with type 2 diabetes","volume":"10","author":"DeVries","year":"2014","journal-title":"European Endocrinol"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822716315352?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822716315352?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T22:24:41Z","timestamp":1536272681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822716315352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":19,"alternative-id":["S0168822716315352"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2016.10.022","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100U\/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2016.10.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}